Garvan Institute of Medical Research

Bisphosphonate drugs have actions in the lung and inhibit the mevalonate pathway in alveolar macrophages

Munoz, M. A.; Fletcher, E. K.; Skinner, O. P.; Jurczyluk, J.; Kristianto, E.; Hodson, M. P.; Sun, S.; Ebetino, F. H.; Croucher, D. R.; Hansbro, P. M.; Center, J. R.; Rogers, M. J.

eLife 10 :e72430, 2021 10.7554/eLife.72430

Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton

Rogers, M. J.; Monkkonen, J.; Munoz, M. A.

BONE 139 :115493, 2020 10.1016/j.bone.2020.115493

Defective Protein Prenylation in a Spectrum of Patients With Mevalonate Kinase Deficiency

Munoz, M. A.; Jurczyluk, J.; Simon, A.; Hissaria, P.; Arts, R. J. W.; Coman, D.; Boros, C.; Mehr, S.; Rogers, M. J.

Frontiers in Immunology 10 :1900, 2019 10.3389/fimmu.2019.01900

Lack of protein prenylation promotes NLRP3 inflammasome assembly in human monocytes

Skinner, O. P.; Jurczyluk, J.; Baker, P. J.; Masters, S. L.; Rios Wilks, A. G.; Clearwater, M. S.; Robertson, A. A. B.; Schroder, K.; Mehr, S.; Munoz, M. A.; Rogers, M. J.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 143 (6) :2315-2317 e3, 2019 10.1016/j.jaci.2019.02.013

From vesicle to cytosol

Rogers, M. J.; Munoz, M. A.

eLife 7 :e38847, 2018 10.7554/eLife.38847

Defective protein prenylation is a diagnostic biomarker of mevalonate kinase deficiency

Munoz, M. A.; Jurczyluk, J.; Mehr, S.; Chai, R. C.; Arts, R. J. W.; Sheu, A.; McMahon, C.; Center, J. R.; Singh-Grewal, D.; Chaitow, J.; Campbell, D. E.; Quinn, J. M. W.; Alexandrov, K.; Tnimov, Z.; Tangye, S. G.; Simon, A.; Phan, T. G.; Rogers, M. J.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 140 (3) :873-875.e6, 2017 10.1016/j.jaci.2017.02.033

A highly sensitive prenylation assay reveals in vivo effects of bisphosphonate drug on the Rab prenylome of macrophages outside the skeleton

Ali, N. ; Jurczyluk, J. ; Shay, G. ; Tnimov, Z. ; Alexandrov, K. ; Munoz, M. A. ; Skinner, O. P. ; Pavlos, N. J. ; Rogers, M. J.;

Small GTPases 30 (4) :637-46, 2015

Dynamics of bivalent chromatin domains upon drug induced reactivation and resilencing in cancer cells

Mayor, R.; Munoz, M.; Coolen, M.W.; Custodio, J.; Esteller, M.; Clark, S.J.; Peinado, M.A.

Epigenetics 6 (9) :1138-1148, 2011

The E3 Ubiquitin Ligase EDD Regulates S-Phase and G(2)/M DNA Damage Checkpoints

Munoz, M. A.;Saunders, D. N.;Henderson, M. J.;Clancy, J. L.;Russell, A. J.;Lehrbach, G.;Musgrove, E. A.;Watts, C. K.;Sutherland, R. L. :

CELL CYCLE 6 (24) :3070-3077, 2007

EDD mediates DNA damage-induced activation of CHK2

Henderson, M. J.;Munoz, M. A.;Saunders, D. N.;Clancy, J. L.;Russell, A. J.;Williams, B.;Pappin, D.;Khanna, K. K.;Jackson, S. P.;Sutherland, R. L.;Watts, C. K. :

JOURNAL OF BIOLOGICAL CHEMISTRY 281 (52) :39990-40000, 2006

Hypermethylation of the prostacyclin synthase (PTGIS) promoter is a frequent event in colorectal cancer and associated with aneuploidy

Frigola, J.;Munoz, M.;Clark, S. J.;Moreno, V.;Capella, G.;Peinado, M. A. :

ONCOGENE 24 (49) :7320-6, 2005

EDD, the human hyperplastic discs protein, has a role in progesterone receptor coactivation and potential involvement in DNA damage response

Henderson, M. J.;Russell, A. J.;Hird, S.;Munoz, M.;Clancy, J. L.;Lehrbach, G. M.;Calanni, S. T.;Jans, D. A.;Sutherland, R. L.;Watts, C. K. :

JOURNAL OF BIOLOGICAL CHEMISTRY 277 (29) :26468-78, 2002

Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor

Sautel, M.;Rudolf, K.;Wittneben, H.;Herzog, H.;Martinez, R.;Munoz, M.;Eberlein, W.;Engel, W.;Walker, P.;Beck-Sickinger, A. G. :

MOLECULAR PHARMACOLOGY 50 (2) :285-92, 1996

High level expression of human neuropeptide Y receptors in mammalian cells infected with a recombinant vaccinia virus

Walker, P.;Munoz, M.;Combe, M. C.;Grouzmann, E.;Herzog, H.;Selbie, L.;Shine, J.;Brunner, H. R.;Waeber, B.;Wittek, R. :